- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Medicamen Biotech has announced a board meeting where it approved the consolidated financial results for the quarter ended June 30, 2025. The Board also signed off on the draft Annual Report for FY24-25. Key appointments include Mr. Ashwani Kumar Sharma as Executive Director for five years, and Mr. Sham Goel and Mr. Shaival Saurabh as Non-Executive Independent Directors. The 32nd AGM is scheduled for September 26, 2025. A final dividend of Re. 1 per equity share (10%) for FY24-25 was also proposed, pending shareholder approval at the AGM.